Samantha Goodman1, Elle Wadsworth1, Gillian Schauer2, David Hammond1. 1. School of Public Health and Health Systems, University of Waterloo, Waterloo, Canada. 2. Department of Health Services, School of Public Health, University of Washington, Seattle, Washington, USA.
Abstract
Objectives: This study aimed to characterize use and perceptions of cannabidiol (CBD) products. Materials and Methods: Participants aged 16-65 years in Canada (n=15,042) and the United States (n=30,288) completed measures on prevalence and patterns of CBD product use and perceptions of CBD oil as part of the 2019 International Cannabis Policy Study online survey. Results: Past 12-month CBD product use was significantly more prevalent among respondents in the United States (26.1%) than in Canada (16.2%). Consumers in the United States and Canada reported using a range of CBD products, including drops (46.3% vs. 47.3%, respectively), topicals (26.0% vs. 16.7%), edibles/foods (23.8% vs. 17.6%), vape oils (18.9% vs. 13.3%), capsules (13.3% vs. 16.7%), and dried flower (10.1% vs. 16.1%). CBD was most commonly reported for management of pain, anxiety, and depression. Over half of CBD consumers in both countries reported that CBD oil was beneficial for health. Conclusions: Use of CBD products is common in both the United States and Canada, primarily to manage self-reported health conditions for which there is little or no evidence of efficacy. Clearer public health messaging regarding the therapeutic effects of CBD is warranted.
Objectives: This study aimed to characterize use and perceptions of cannabidiol (CBD) products. Materials and Methods: Participants aged 16-65 years in Canada (n=15,042) and the United States (n=30,288) completed measures on prevalence and patterns of CBD product use and perceptions of CBD oil as part of the 2019 International Cannabis Policy Study online survey. Results: Past 12-month CBD product use was significantly more prevalent among respondents in the United States (26.1%) than in Canada (16.2%). Consumers in the United States and Canada reported using a range of CBD products, including drops (46.3% vs. 47.3%, respectively), topicals (26.0% vs. 16.7%), edibles/foods (23.8% vs. 17.6%), vape oils (18.9% vs. 13.3%), capsules (13.3% vs. 16.7%), and dried flower (10.1% vs. 16.1%). CBD was most commonly reported for management of pain, anxiety, and depression. Over half of CBD consumers in both countries reported that CBD oil was beneficial for health. Conclusions: Use of CBD products is common in both the United States and Canada, primarily to manage self-reported health conditions for which there is little or no evidence of efficacy. Clearer public health messaging regarding the therapeutic effects of CBD is warranted.
Entities:
Keywords:
cannabidiol; cannabis; marijuana; perceptions; substance use
Authors: Ulf Meier; Franz Dussy; Eva Scheurer; Katja Mercer-Chalmers-Bender; Sarah Hangartner Journal: Forensic Sci Int Date: 2018-08-11 Impact factor: 2.395
Authors: Michael S Dunbar; Rachana Seelam; Joan S Tucker; Caislin L Firth; Eric R Pedersen; David J Klein; Anthony Rodriguez; Elizabeth J D'Amico Journal: Addict Behav Date: 2021-11-20 Impact factor: 3.913
Authors: Janni Leung; Gary Chan; Daniel Stjepanović; Jack Yiu Chak Chung; Wayne Hall; David Hammond Journal: Psychopharmacology (Berl) Date: 2022-01-12 Impact factor: 4.415
Authors: Ka Yan Ho; Ka Wai Katherine Lam; Edmond Tak Fai Tong; Shara Ho; Cynthia Sau Ting Wu; Man Nok Tong; Lai Ngo Tang; Yim Wah Mak Journal: Int J Environ Res Public Health Date: 2022-09-14 Impact factor: 4.614